Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD) : position document of the Belgian IBD Research & Development Group (BIRD)

被引：0

作者：

Vermeire, Severine ^{[1
]}

Louis, Edouard ^{[2
]}

Dewit, Olivier ^{[3
]}

Franchimont, Denis ^{[4
]}

Moreels, Tom ^{[3
]}

Ferrante, Marc ^{[1
]}

Rahier, Jean-Francois ^{[4
,5
]}

Van Hootegem, Philippe ^{[6
]}

De Vos, Martine ^{[7
]}

Mana, Fazia ^{[8
]}

Baert, Filip ^{[9
]}

机构：

[1] Univ Hosp Leuven, Dept Gastroenterol, B-3000 Leuven, Belgium

[2] Ctr Hosp Univ Liege, Dept Gastroenterol, Liege, Belgium

[3] Clin Univ St Luc UCL Bruxelles, Dept Gastroenterol, Brussels, Belgium

[4] Hop Erasme Brussels, Dept Gastroenterol, Brussels, Belgium

[5] CHU UCL Mt Godinne, Dept Gastroenterol, Yvoir, Belgium

[6] AZ Sint Lucas Brugge, Dept Gastroenterol, Brugge, Belgium

[7] Univ Ghent, Univ Hosp, Dept Gastroenterol, B-9000 Ghent, Belgium

[8] Free Univ Brussels, Univ Hosp, Dept Gastroenterol, B-1050 Brussels, Belgium

[9] AZ Delta Roeselare, Dept Gastroenterol, Roeselare, Netherlands

来源：

ACTA GASTRO-ENTEROLOGICA BELGICA | 2015年 / 78卷 / 01期

关键词：

biosimilar; Crohn's disease; ulcerative colitis; inflammatory bowel disease; anti-TNF; INNOVATOR INFLIXIMAB; PARALLEL-GROUP; DOUBLE-BLIND; STATEMENT; EFFICACY; SAFETY; CT-P13;

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：26 / 29

页数：4

共 8 条

[1] Argüelles-Arias F, 2013, REV ESP ENFERM DIG, V105, P37, DOI 10.4321/S1130-01082013000100006
[2] ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
Danese, Silvio
Gomollon, Fernando
[J]. JOURNAL OF CROHNS & COLITIS, 2013, 7 (07) : 586 - 589
[3] Federal Agency for Medicines and Health Products (FAGG/AFMPS), BIOS TOP
[4] Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012
Kay, Jonathan
Feagan, Brian G.
Guirguis, Micheal S.
Keystone, Edward C.
Klein, Agnes V.
Lubiniecki, Anthony S.
Mould, Diane R.
Nyarko, Kwasi A.
Ridgway, Anthony A. G.
Trudeau, Maureen E.
Wang, Jian
[J]. BIOLOGICALS, 2012, 40 (06) : 517 - 527
[5] Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology
Mularczyk, Aldona
Gonciarz, Maciej
Bartnik, Witold
Durlik, Marek
Eder, Piotr
Gasiorowska, Anita
Linke, Krzysztof
Lodyga, Michal
Lykowska-Szuber, Liliana
Malecka-Panas, Ewa
Pawlik, Magdalena
Radwan, Piotr
Rydzewska, Grazyna
[J]. PRZEGLAD GASTROENTEROLOGICZNY, 2014, 9 (01): : 1 - 3
[6] A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Park, Won
Hrycaj, Pawel
Jeka, Slawomir
Kovalenko, Volodymyr
Lysenko, Grygorii
Miranda, Pedro
Mikazane, Helena
Gutierrez-Urena, Sergio
Lim, MieJin
Lee, Yeon-Ah
Lee, Sang Joon
Kim, HoUng
Yoo, Dae Hyun
Braun, Juergen
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (10) : 1605 - 1612
[7] Biosimilars: the science of extrapolation
Weise, Martina
Kurki, Pekka
Wolff-Holz, Elena
Bielsky, Marie-Christine
Schneider, Christian K.
[J]. BLOOD, 2014, 124 (22) : 3191 - 3196
[8] A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Yoo, Dae Hyun
Hrycaj, Pawel
Miranda, Pedro
Ramiterre, Edgar
Piotrowski, Mariusz
Shevchuk, Sergii
Kovalenko, Volodymyr
Prodanovic, Nenad
Abello-Banfi, Mauricio
Gutierrez-Urena, Sergio
Morales-Olazabal, Luis
Tee, Michael
Jimenez, Renato
Zamani, Omid
Lee, Sang Joon
Kim, HoUng
Park, Won
Mueller-Ladner, Ulf
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (10) : 1613 - 1620

← 1 →